European Journal of Integrative Medicine
Volume 1, Issue 1 , Pages 27-33 , April 2009

A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients

  • Alessandra Longhi

      Affiliations

    • Chemotherapy Division, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +390516366374; fax: +390516366277.
    • ,
  • Erminia Mariani

      Affiliations

    • Immunology and Genetics Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy
    • ,
  • Jürgen J. Kuehn

      Affiliations

    • Lukas Clinic, Arlesheim, Switzerland

Received 28 December 2008 ,Revised 29 January 2009 ,Accepted 2 February 2009.

References 

  1. Briccoli A. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005;104(8):1721–1725
  2. Fagioli F. High dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol. 2002;20(8):2150–2156
  3. Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli Institute in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748–755
  4. Kebudi R. Oral Etoposide in pediatric sarcoma patients. Pediatr Blood Cancer. 2004;42(4):320–324
  5. Sandri A, Massimino M, Mastrodicasa L, Sardi N, Bertin D, Basso ME, et al. Treatment with oral etoposide for childhood recurrent ependymomas. J Pediatr Hematol Oncol. 2005;27(9):486–490
  6. Hugo F, Dittmar T, Treutler EK, Zänker KS, Kuehn JJ. The viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-non-Hodgkin's lymphoma cell lines. Onkologie. 2005;28:415–420
  7. Mueller E, Anderer FA. A viscum album oligosaccaride activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother. 1990;32:221–227
  8. Braun JM, Ko HL, Schierholtz JM, Beuth J. Standardized mistletoe extract augments immune response and down regulates local and metastatic tumor growth in murine models. Anticancer Res. 2002;22(6C):4187–4190
  9. Schaffrath B, Mengs U, Schwarz T, Hilgers RD, Beuth J, Möckel B, et al. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Res. 2001;21(6A):3981–3987
  10. Kuttan G, Menon LG, Antony S, Kuttan R. Anticarcinogenic and antimetastatic activity of Iscador. Anticancer Drugs. 1997;8(Suppl. 1):S15–S16
  11. Hajto T, Hostanska K, Gabius HU. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res. 1990;50:3322–3326
  12. Chernyshov VP, Heusser P, Omelchenko LI, Chernychova LI, Vodyanik MA, Vykhovanets EV, et al. Immunomodulatory and clinical effects of Viscum album (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the Chernobyl nuclear accident. Am J Ther. 2000;7(3):195–203
  13. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer—a systematic review on controlled clinical trials. Eur J Med Res. 2003;8(3):109–119
  14. Mockel B, Schwarz T, Zinke H, Eck J, Langer M, Lentzen H, et al. Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines. Arzneim-Forsch/Drug Res. 1997;47(10):1145–1151
  15. Van Huyen J, Bayry J, Delignat S, Gaston AT, Michel O, Bruneval P, et al. Induction of apoptosis of endothelial cells by Viscum album, a role for anti-tumoral properties of mistletoe lectins. Mol Med. 2002;8(10):600–606
  16. Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, et al. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol. 2004;15(12):1816–1824
  17. Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. Eur J Cancer. 2004;40(3):390–402
  18. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008;(2):CD003297
  19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655
  20. Blair GE, Cook GP. Cancer and immune system. An overview. Oncogene. 2008;27:5868
  21. Muller CR, Smeland S, Bauer HC, Sater G, Strander H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hosp series. Acta Oncol. 2005;44(5):475–480
  22. Meyers PA, Schwartz CL, Krailo MD. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633–638

PII: S1876-3820(09)00009-2

doi: 10.1016/j.eujim.2009.02.005

European Journal of Integrative Medicine
Volume 1, Issue 1 , Pages 27-33 , April 2009

Article Tools

* Image Usage & Resolution